Show simple item record

Real-world evidence of TNF inhibition in axial spondyloarthritis : can we generalise the results from clinical trials?

dc.contributor.authorJones, Gareth T.
dc.contributor.authorDean, Linda E.
dc.contributor.authorPathan, Ejaz
dc.contributor.authorHollick, Rosemary J.
dc.contributor.authorMacfarlane, Gary J.
dc.date.accessioned2020-04-27T08:00:01Z
dc.date.available2020-04-27T08:00:01Z
dc.date.issued2020-07
dc.identifier160881718
dc.identifierd11bef00-ba4b-481a-aa57-51ac6fc9dfcf
dc.identifier85083707435
dc.identifier32327428
dc.identifier32327428
dc.identifier000542734200021
dc.identifier.citationJones , G T , Dean , L E , Pathan , E , Hollick , R J & Macfarlane , G J 2020 , ' Real-world evidence of TNF inhibition in axial spondyloarthritis : can we generalise the results from clinical trials? ' , Annals of the Rheumatic Diseases , vol. 79 , no. 7 , pp. 914-919 . https://doi.org/10.1136/annrheumdis-2019-216841en
dc.identifier.issn0003-4967
dc.identifier.otherORCID: /0000-0003-2322-3314/work/73119670
dc.identifier.otherORCID: /0000-0001-6558-7189/work/79062974
dc.identifier.otherORCID: /0000-0003-0016-7591/work/83703972
dc.identifier.urihttps://hdl.handle.net/2164/14166
dc.descriptionFunding This work was supported by the British Society for Rheumatology (BSR) who funded the BSRBR-AS. The BSR received funding for this from Pfizer, AbbVie and UCB. These companies receive advance copies of manuscripts for comments but have no input in to the topics for analysis in the register nor the work involved in undertaking analysis. Analysis of data was supported by the Versus Arthritis/Medical Research Council Centre for Musculoskeletal Health and Work (grant number 20665).en
dc.format.extent6
dc.format.extent294958
dc.language.isoeng
dc.relation.ispartofAnnals of the Rheumatic Diseasesen
dc.subjectankylosing spondylitisen
dc.subjectanti-TNFen
dc.subjectepidemiologyen
dc.subjectspondyloarthritisen
dc.subjectBSRen
dc.subjectANKYLOSING-SPONDYLITISen
dc.subjectBATHen
dc.subjectR Medicine (General)en
dc.subjectGeneral Biochemistry,Genetics and Molecular Biologyen
dc.subjectImmunology and Allergyen
dc.subjectRheumatologyen
dc.subjectImmunologyen
dc.subjectMedical Research Council (MRC)en
dc.subject20665en
dc.subjectArthritis Research UK (ARUK)en
dc.subject.lccR1en
dc.titleReal-world evidence of TNF inhibition in axial spondyloarthritis : can we generalise the results from clinical trials?en
dc.typeJournal articleen
dc.contributor.institutionUniversity of Aberdeen.Other Applied Health Sciencesen
dc.contributor.institutionUniversity of Aberdeen.Epidemiology Groupen
dc.contributor.institutionUniversity of Aberdeen.Institute of Applied Health Sciencesen
dc.contributor.institutionUniversity of Aberdeen.Aberdeen Centre for Arthritis and Musculoskeletal Health (ACAMH)en
dc.contributor.institutionUniversity of Aberdeen.Centre for Health Data Scienceen
dc.contributor.institutionUniversity of Aberdeen.Vice Principalsen
dc.description.statusPeer revieweden
dc.identifier.doi10.1136/annrheumdis-2019-216841
dc.identifier.urlhttp://www.scopus.com/inward/record.url?scp=85083707435&partnerID=8YFLogxKen


Files in this item

Thumbnail
Name:
Jones_et_al_ARD_RealWorldEvide ...
Size:
288.0Kb
Format:
PDF
View/Open

This item appears in the following Collection(s)

Show simple item record